RCAMU
SUPN icon

Rothschild & Co Asset Management US’s Supernus Pharmaceuticals SUPN Stock Holding History

Rothschild & Co Asset Management US’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-734,267
Closed -$17.4M – 365
2019
Q4 		$17.4M Sell
734,267
-36,695
-5% -$891K 0.18% 205
2019
Q3 		$21.2M Sell
770,962
-10,964
-1% -$325K 0.23% 183
2019
Q2 		$25.9M Sell
781,926
-66,873
-8% -$2.29M 0.28% 156
2019
Q1 		$29.7M Sell
848,799
-2,684
-0.3% -$99.9K 0.32% 117
2018
Q4 		$28.3M Buy
851,483
+15,455
+2% +$665K 0.34% 107
2018
Q3 		$42.1M Sell
836,028
-21,092
-2% -$1.04M 0.43% 71
2018
Q2 		$51.3M Sell
857,120
-222,668
-21% -$11.5M 0.55% 44
2018
Q1 		$49.5M Sell
1,079,788
-7,627
-0.7% -$318K 0.55% 47
2017
Q4 		$43.3M Sell
1,087,415
-39,803
-4% -$1.57M 0.46% 66
2017
Q3 		$45.1M Sell
1,127,218
-45,647
-4% -$1.98M 0.5% 58
2017
Q2 		$50.5M Buy
1,172,865
+43,007
+4% +$1.53M 0.57% 46
2017
Q1 		$35.4M Buy
1,129,858
+35,981
+3% +$964K 0.41% 71
2016
Q4 		$27.6M Buy
1,093,877
+148,520
+16% +$3.32M 0.35% 88
2016
Q3 		$23.4M Buy
945,357
+52,806
+6% +$1.2M 0.4% 83
2016
Q2 		$18.2M Buy
892,551
+110,320
+14% +$1.96M 0.33% 104
2016
Q1 		$11.9M Buy
782,231
+118,482
+18% +$1.55M 0.22% 155
2015
Q4 		$8.92M Buy
663,749
+72,920
+12% +$1.13M 0.16% 203
2015
Q3 		$8.29M Buy
590,829
+203,875
+53% +$3.79M 0.16% 207
2015
Q2 		$6.57M Buy
+386,954
New +$5.51M 0.12% 239

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Rothschild & Co Asset Management US's SUPN Position: Q1 2020 in Review

Rothschild & Co Asset Management US sold out of Supernus Pharmaceuticals (SUPN) in Q1 2020, closing a stake of 734,267 shares — an estimated $17.4M sold.

Rothschild & Co Asset Management US first reported a position in SUPN in Q2 2015 and held it in 19 quarters. The position peaked at $51.3M in Q2 2018. 208 funds tracked by Wall St. Rank hold SUPN as of Q1 2020.

  • Rothschild & Co Asset Management US reported no remaining Supernus Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Rothschild & Co Asset Management US sold 734,267 Supernus Pharmaceuticals shares in Q1 2020, an estimated $17.4M.
  • Rothschild & Co Asset Management US first reported a position in Supernus Pharmaceuticals in Q2 2015 and held it in 19 quarters.
  • Rothschild & Co Asset Management US's Supernus Pharmaceuticals position peaked at $51.3M in Q2 2018.
  • 208 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2020.

Based on Rothschild & Co Asset Management US's 13F filing for Q1 2020, filed 14 May 2020.